Cathie Wood's $362 Million CRISPR Bet: Hidden Catalyst
Cathie Wood’s big bet on CRISPR Therapeutics signals more than faith in gene editing. This article digs into the unde...
This section explains why investors might choose an Equal Weighted Index, focusing on balanced exposure and straightforward rebalancing.
22,679 articlesCathie Wood’s big bet on CRISPR Therapeutics signals more than faith in gene editing. This article digs into the unde...
Celcuity stock popped today after the company released its 2025 results, showing a tighter quarterly loss despite no ...
MP Materials is capturing attention as the only fully integrated u.s. rare earth producer. With buzz around potential...
A $100,000 investment in Dividend Kings targets $5,400 of passive income each year, reflecting durable payouts amid a...
CareCloud's Q1 2026 earnings outlook offers clues about growth, margins, and execution. This guide breaks down the si...
Poet Technologies stock sold off again as investors weigh dilution, growth prospects, and market jitters. This analys...
A sudden price collapse in a toll-tech stock creates a rare chance for patient investors. This guide explains how to ...
MP Materials sits at the intersection of U.S. manufacturing ambitions and global rare-earth supply. This guide breaks...
Oklo has faced a challenging six months as the stock trended lower with little revenue to show. This article explores...
Crescent Capital BDC offers a high-yield opportunity along with risks linked to debt investments. This guide breaks d...
Tech ETFs split into three paths in 2026: broad mega-cap funds stumble, cybersecurity themes gain ground, and AI infr...
The Baupost founder made a bold, selective move: trim a large Alphabet stake and pivot to a fintech name that slumped...